Advertisement

Germany's CureVac enrols first participant in pivotal study of COVID-19 vaccine

Follow The Hawk on Google News+ Follow

Advertisement

Berlin: Germany's CureVac announced on Monday that it has enrolled the first participant in the Phase 2b/3 study of its COVID-19 vaccine candidate.

The trial will assess the safety and efficacy in adults and is expected to include more than 35,000 participants in Europe and Latin America, it added in a statement.

Advertisement

—Reuters

Also readFSSAI to initiate action against Bisleri over unsafe water sample

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST